Aurobindo Pharma announces ₹800 crore share buyback; check record date and other key details

The company said its board has approved the share buyback of up to 54,23,728 fully paid-up equity shares of the company, each having a face value of ₹1, representing up to 0.93% of the total number of equity shares in the paid-up equity share capital of the company.

The price for the same is set at the price of ₹1,475 per equity share (“Buyback Price”) payable in cash for an aggregate amount up to ₹800 crore.

Record Date

The company has set April 17, 2026, as the record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback, in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations.

Buyback details

Aurobindo Pharma share price

Shares of the company were trading 0.22% lower at ₹1,330.80 apiece on the NSE.

Aurobindo Pharma Q3 FY26 earnings

Aurobindo Pharma said its consolidated net profit increased 8% year-on-year to ₹910 crore for the December quarter, led by robust sales in Europe and the US.

The Hyderabad-based drug major reported a net profit of $846 crore for the October-December period of the last fiscal year.

Total revenue from operations increased to ₹8,646 crore during the quarter as compared with ₹7,979 crore in the year-ago period, the drug firm said in a statement.

"Q3 reflected steady execution across Aurobindo's core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the US and Europe," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said.

Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability, he added.

"As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term," Reddy said.